Clicky

MannKind Corporation(NNFN)

Description: MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.


Keywords: Biopharmaceutical Diabetes Rare Diseases Orphan Drug Therapeutic Products Insulin Idiopathic Pulmonary Fibrosis Pulmonary Arterial Hypertension Pulmonary Fibrosis Pulmonary Hypertension Treprostinil Interstitial Lung Disease Insulin Delivery Lung Disorders Nintedanib Afrezza Inhalable Insulin Mannkind Corporation Tyvaso

Home Page: www.mannkindcorp.com

1 Casper Street
Danbury, CT 06810
United States
Phone: 818 661 5000


Officers

Name Title
Dr. Michael E. Castagna Pharm.D. CEO & Director
Ms. Lauren M. Sabella Chief Operating Officer
Dr. David B. Thomson J.D., Ph.D. Executive VP, General Counsel & Secretary
Dr. Stuart A. Tross Ph.D. Executive VP and Chief People & Workplace Officer
Mr. Christopher B. Prentiss M.B.A. Chief Financial Officer
Mr. Sanjay Singh M.B.A. Executive Vice President of Technical Operations
Ms. Rosabel Realica Alinaya CPA VP of Investor Relations & Treasury
Mr. John F. Bedard Senior Vice President of Worldwide Regulatory Affairs
Mr. James Patrick McCauley Jr., J.D., M.B.A. Chief Commercial Officer
Dr. Burkhard Blank M.D. Executive VP of Research & Development and Chief Medical Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 39.2157
Trailing PE: 78.85
Price-to-Book MRQ: 0
Price-to-Sales TTM: 6.6077
IPO Date:
Fiscal Year End: December
Full Time Employees: 411
Back to stocks